CLINICAL_TRIALS
trial_result
· 2025-05-23
Clinical Trial Update: A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Summary
Phase 2 study of blinatumomab in relapsed or refractory indolent non-Hodgkin lymphoma has been terminated. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-05-23